Synthesis, characterization, DFT studies, and molecular modeling of hydrazinelidene‐3‐oxo‐3‐(p‐olyl) propanal derivatives as potential candidate for Hepatitis B and C treatment

Abstract

Serious liver conditions including cirrhosis, hepatocellular carcinoma, and liver failure can be brought on by hepatitis B and C (HBV and HCV) infection. In our study, compound H_B and H_E were synthesized, spectroscopically, theoretically characterized, and investigated as potential drug for HBV and HCV. The stability of the investigated compounds as well as their Inter‐ and intramolecular interactions were investigated using the density functional theory with the B3LYP/6‐311+G (d, p) basis set. Lower energy gaps for studied compounds indicate compound ds to be reactive. The maximal absorption wavelengths of the substances under investigation were ascertained using the UV absorption spectrum. The optical property of the compounds under investigation was also calculated. Various vibrational modes displayed by functional groups present in the examined compounds were considered. Thereafter, docking was performed to determine the compatibility of compounds in study with selected hepatitis B and C proteins in comparison to recommended drugs Sofosbuvir and lamivudine. The results of molecular docking were based on binding affinity. Compound H_E, with a binding affinity of ‐7.6 kcal/mol has more potential in treating hepatitis than H_B, which has a binding affinity of ‐7.1 kcal/mol and is also a better anti‐hepatic agent than standard drugs sofosbuvir and lamivudine with lower binding affinities. Hence, H_E has the potential to treat HBV and HCV.